A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and functional status in pulmonary hypertension (IRON-PH)

Condition studied

Pulmonary hypertension, Iron deficiency

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change in 6MWD from baseline to 24 weeks follow-up

Endpoint detail

Change in EQ5D from baseline to 24 weeks follow-up, Change in MLHFQ from baseline to 24 weeks follow-up, Change in FSS from baseline to 24 weeks follow-up, The hazard ratio between treatment arms in developing a composite clinical worsening event in the overall trial population (from first patient visit to last patient visit)